

# Effects of Lactobacillales Supplementation in a Rat Model of Short Bowel Syndrome (SBS)

A. GARRIGUES; N. Pourtier; I. Savary-Auzeloux; L. Ribeiro; M. Roy; A. Dumay; A. Bado; N. Kapel; M. Le Gall; M. Thomas; J. Le Beyec - Le Bihan (No conflict of interest)


**Alice GARRIGUES**  
2<sup>nd</sup> year of PhD




# Short Bowel Syndrome (SBS)

## Spontaneous adaptations


### Morphological intestinal adaptation



### Functional intestinal adaptation



### Nutritional support through parenteral nutrition




Extensive resection  
of the intestine

Post-duodenal length  
 $< 1,5 - 2\text{m}$

**Severe MALABSORPTION**  
**First cause of chronic intestinal failure**

### Modification of eating behavior



### Microbiota modification




**Control**      **SBS**  
90% *Lactobacillus*  
*Lactobiota*




# Adaptations in a pre-clinical model of SBS

## Spontaneous adaptations


### Morphological intestinal adaptation




### Functional intestinal adaptation



### Modification of eating behavior



### Microbiota modification



Key factor?

# SBS Microbiota : Role in the adaptations setting


## Previous studies in our team:

- Transfer of SBS microbiota to axenic rats  
→ Setting of adaptations observed in SBS patients : SBS-like Microbiota + High concentrations of GLP-1 and ghrelin  
*Gillard et al, 2017*
- Level of food intake in SBS rats positively correlated with Lactobacillaceae abundance  
*Fourati et al, 2023*
- Muriel Thomas' team (INRAE, Micalis) → Isolation of probiotic *Lactobacillus* strains from the SBS microbiota  
*Giron et al, 2021*

## AIM :


→ Study the effect of supplementation with 2 strains on the setting of spontaneous adaptations in a rat model of short bowel syndrome.

# Design of the experiment




# Microbiota composition and alpha/beta diversity after 1 month of supplementation

D28





- Large majority of Lactobacillaceae in the SBS microbiota
- Reduced alpha and beta diversities in SBS rats

→ No major changes in the microbiota composition with the supplementation




In collaboration with  
Anne DUMAY and Maryline ROY

# Impact of strains A or B supplementation on SBS phenotype




- Increased food intake in SBS rats
- SBS+B rats eat less than the others SBS groups

● SHAM  
● SBS  
● SBS+A  
● SBS+B




**Feces score:**

- 6 = severe diarrhea
- 5 = diarrhea
- 4 = soft feces + diarrhea
- 3 = soft feces
- 2 = moulded feces + soft feces
- 1 = moulded feces



Less diarrhea with slowed transit time in SBS supplemented groups



# Measurements of jejunum and colon lengths in SBS rats





- Increased jejunum and colon lengths in SBS rats at D28
- No effect of the supplementation with the two strains on these parameters

# Jejunal and colonic hyperplasia analysis

D28





- SHAM
- SBS
- SBS+A
- SBS+B





- Increased depth of the jejunal and colic crypts in all SGC rats
- No major effects of the supplementation on these parameters

# Measurement of the Thickness of the Jejunal Muscularis in SBS Rats





- Significant increase in jejunal muscularis thickness in treated SBS rats, particularly in SBS+B rats.



# Conclusion

## Impact of *Lactobacillales* Supplementation

- ↓ of food intake in **SGC+B** : gain as many weight as the other groups  
→ **positive effect of the strain B on weight gain?**
- Improvement in faeces : less diarrhea  
→ **better water absorption?**
- Improved transit time : more time for nutrient absorption  
→ **positive effect on absorption?**
- ↗ in the thickness of the jejunal muscularis  
→ **positive effect on absorption?**



**Strains A and B appear to have had a positive effect on different parameters**

→ Could they be an effective therapy?

→ Efficacy compared to existing therapies?

# Acknowledgements to all AdMIR project partners



## U1149, PIMS team :

### Team Leaders

Le Gall Maude

Bado André

### Équipe : Viennois / Meinzer

Anne Dumay

Maryline Roy

### Researches

Duboc Henri

Joly Francisca

Le Beyec Le Bihan Johanne

Ledoux Séverine

Moszkowicz David

Msika Simon

Poghosyan Tigran

Ribeiro-Parenti Lara

Hedjoudje Abdellah

### Research assistants

Sharhour Hounayda

Willemetz Alexandra

### PhD students

Vaugrente Amélie

Hirlemann Mélanie



### Probihote team:

Thomas Muriel

Cherbuy Claire

Bruneau Aurelia

Le Poupon Claire



### DMU BioGeM, APHP UMR S1139 :

Pr. Nathalie Kapel



FHU PaCeMM